Prevalence Study of Adrenal Suppression After Corticosteroids During Chemotherapy
2017年3月23日 更新者:University of Colorado, Denver
A Prevalence Study of Adrenal Suppression After Adjuvant Corticosteroid Administration During Gynecologic Cancer Chemotherapy
Gynecologic Oncology patients have several different chemotherapy regimens, and dexamethasone is now routinely given to prevent allergic reactions to the chemotherapeutic agents.
The most common chemotherapeutic agents used are paclitaxel and carboplatin.
This combination regimen is given every three weeks for a total of 5-6 doses.
Each dose is given after administration of 20 mg dexamethasone twelve hours prior to and the morning of chemotherapy.
Dexamethasone is used for its antiemetic effects, but also to minimize the potentially fatal hypersensitivity reaction that can occur with paclitaxel.
Another commonly used chemotherapy regimens is weekly cisplatin given with one dose of dexamethasone for cervical cancer.
Chronic steroids are known to cause adrenal suppression, but it is not known if the amount of dexamethasone given with the gynecologic cancer chemotherapy regimens described above causes adrenal insufficiency in these patients.
The investigators hypothesis is that some women receiving steroids with their chemotherapy may have adrenal insufficiency, and that they will have greater than normal chemotherapy-related fatigue.
研究概览
详细说明
This is a non-blinded, non-randomized, non-interventional prospective cohort study to evaluate the prevalence of adrenal suppression in gynecologic cancer patients undergoing chemotherapy regimens requiring concurrent dexamethasone.
Women with gynecologic cancers (including cervical, endometrial, ovarian, fallopian tube, or primary peritoneal cancers) who are scheduled to begin chemotherapy with any of the standard chemotherapy regimens that also receive dexamethasone.
After informed consent is obtained, they will have peripheral blood samples drawn at the time of routine blood draw for (ideally a fasting morning) cortisol level at three different times in their routine care.
Patients will also answer a quality of life questionnaire at the times of these blood draws to assess for symptoms associated with treatment (nausea, vomiting, fatigue).
A total of 80 subjects will be recruited to participate.
40 subjects will be given chemotherapy regimens receiving dexamethasone with three chemotherapy treatments in a three week cycle.
40 subjects will be given chemotherapy regimens receiving dexamethasone with one chemotherapy treatment in a three week cycle.
研究类型
观察性的
注册 (实际的)
19
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Colorado
-
Aurora、Colorado、美国、80045
- University of Colorado Denver Anschutz Medical Campus
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
女性
取样方法
非概率样本
研究人群
The study will be open to all women over the age of 18 scheduled to begin standard of care chemotherapy for a gynecologic malignancy, either every 3 weeks (carboplatin and taxol) or weekly (cisplatin).
The study is restricted by gender due to the population of interest being women with gynecologic malignancies.
描述
Inclusion Criteria:
- Patients must have age greater or equal to 18
- Patients with histologic diagnosis of cervical, endometrial, or ovarian cancer who are receiving chemotherapy
- Any clinical stage allowed
- GOG performance status 0, 1, or 2
- Written informed consent and HIPAA authorization obtained prior to any initiation of study procedures
Exclusion Criteria:
- The presence of other comorbid conditions known to impact adrenal function, whether primary adrenal dysfunction, or dysfunction due to administration of steroids for treatment (Addison's or Cushings disease, pituitary or hypothalamic disease, systemic lupus erythematosis, rheumatoid arthritis, asthma)
- Patients who have received chronic or pulsed steroids within the past 9 months.
- Patients with previous diagnosis of adrenal suppression.
- Underlying psychiatric condition which would, in the opinion of the investigator, preclude compliance with study requirements
- Women who are pregnant are not eligible to participate.
- Patients who have received prior radiotherapy or chemotherapy for an abdominal or pelvic tumor are excluded. Prior radiation or adjuvant chemotherapy for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than 3 years prior to registration, and the patient remains free of recurrent or metastatic disease.
- Patients with invasive malignancies, with exception of non-melanoma skin cancer, and specific malignancies noted above, who had (or have) any evidence of other cancer present within the last 5 years or whose previous cancer treatment contraindicates this protocol are excluded.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Chemotherapy every 3 weeks
One treatment of chemotherapy every 3 weeks.
Chemotherapy will either be 2 doses of 20 mg orally (PO) (12 hrs prior and immediately before treatment) or 1 dose via IV.
The total dose per cycle is 20-40 mg every 3 weeks for 18 weeks.
|
This study is designed only to look at the prevalence of adrenal suppression during chemotherapy.
If adrenal suppression is detected, treatment will be off-study at the treating physician's discretion.
其他名称:
|
|
Weekly chemotherapy
Chemotherapy will be given three times in a three week cycle.
Chemotherapy will be given either Day 1, 8, and day 15 or Day 1,2 and day 8).
Chemotherapy will either be 2 doses of 20 mg PO (12 hrs priors and immediately before treatment) or 1 dose via IV.
The total dose per cycle will be 20-40 mg approximately for 18 weeks.
|
This study is designed only to look at the prevalence of adrenal suppression during chemotherapy.
If adrenal suppression is detected, treatment will be off-study at the treating physician's discretion.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Identify the level of adrenal suppression with recurrent, intermittent steroid administration during gynecologic chemotherapy regimens in all participating patients
大体时间:6 months
|
This will be done by testing a morning cortisol level in patients at the time of routine blood draw at three different time points in each patient's chemotherapy regimen.
|
6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Identify the differences in quality of life scores among patients with adrenal suppression and those with normal function
大体时间:6 months
|
Differences in quality of life scores will be measured using a modified FACT-G questionnaire
|
6 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Monique A Spillman, MD、University of Colorado Denver Anschutz Medical Center
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2010年2月1日
初级完成 (实际的)
2015年11月1日
研究完成 (实际的)
2015年11月1日
研究注册日期
首次提交
2010年9月23日
首先提交符合 QC 标准的
2010年9月24日
首次发布 (估计)
2010年9月27日
研究记录更新
最后更新发布 (实际的)
2017年3月24日
上次提交的符合 QC 标准的更新
2017年3月23日
最后验证
2017年3月1日
更多信息
与本研究相关的术语
其他研究编号
- 10-0190.cc
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.